Working with its clients to ensure a successful outcome in terms of market access, Grove consultants based in the Lithuanian market provide expert advice in three key areas:
The National Drug Policy was approved in August 2017 in Lithuania. While the main aim of the policy is to ensure universal healthcare provision to all within the country, reducing patient co-payment is a key element and with this, pricing policies have been scrutinized. Although recent legislation has improved the transparency of the Lithuanian pharmaceutical market to a limited degree, the regulatory authorities still have work to do in getting to grips with eliminating fluctuations in supply caused by parallel exports.
The local reimbursement system continues to reflect inefficiency and poor management within the healthcare system as a whole. With a lack of health-related data, processing abilities and methodologies required, Lithuania is still some way from being able to implement an effective value- based reimbursement policy. The SMCA recognizes the failings, but it will take considerable time before there is real transparency and efficiency within the reimbursement system in the country.
The State Medicines Control Agency (SMCA) and the Ministry of Health both have key roles in the market for medicines, medical devices, food supplements and cosmetics.
New market entrants continue to find it a challenge to navigate reimbursement policies in the Lithuanian market. With experienced local consultants, Grove can assist with: